Dynavax Technologies

DVAX Small Cap

Healthcare · Drug Manufacturers - Specialty & Generic

Updated: Apr 5, 2026, 17:43 UTC

$15.50

+0% today

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

46.97x

Forward Price/Earnings

P/S Ratio

5.51x

Price-to-Sales

EV/EBITDA

60.37x

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$1.8B

Market Capitalization

Revenue Growth

17.7%

YoY Revenue Growth

Profit Margin

-13.13%

Net profit margin

ROE

-7.14%

Return on Equity

Beta

0.93

Market sensitivity

Short Interest

13.19%

% of float sold short

Avg. Volume

3,223,007

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

1 analysts

Avg. Price Target

$16.00

+3.23% upside

Target Range

$16.00 – $16.00

About the Company

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defe

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic Country: United States Employees: 405 Exchange: NMS